Kandane-Rathnayake, Rangi and Louthrenoo, Worawit and Golder, Vera and Luo, Shue-Fen and Wu, Yeong-Jian J. and Lateef, Aisha and Cho, Jiacai and Li, Zhanguo and An, Yuan and Hamijoyo, Laniyati and Navarra, Sandra and Zamora, Leonid and Katsumata, Yasuhiro and Harigai, Masayoshi and Sockalingam, Sargunan and Chan, Madelynn and Chen, Yi-Hsing and O'Neill, Sean and Goldblatt, Fiona and Hao, Yanjie and Zhang, Zhuoli and Kikuchi, Jun and Takeuchi, Tsutomu and Lau, Chak Sing and Nikpour, Mandana and Morand, Eric and Hoi, Alberta and Collaboration, Asia Pacific Lupus (2021) Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: A longitudinal, multinational study. Rheumatology, 60 (11). pp. 5185-5193. ISSN 1462-0324, DOI https://doi.org/10.1093/rheumatology/keab217.
Full text not available from this repository.Abstract
The prevalence and associations of leucopenia in SLE remain incompletely understood. We evaluated associations of disease activity and medication use with leucopenia (lymphopenia and neutropenia) in a multinational, prospectively followed SLE cohort. Methods. Data from the Asia Pacific Lupus Collaboration cohort, in which disease activity and medications were prospectively captured from 2013 to 2018, were used. Predictors of lymphopenia (lymphocyte count <0.8 x 109/l) and neutropenia (neutrophil count <1.5 x 10(9)/l) were examined using multiple failure, time-dependent survival analyses. Results. Data from 2330 patients and 18 287 visits were analysed. One thousand and eighteen patients (43.7%) had at least one episode of leucopenia; 867 patients (37.2%) had lymphopenia, observed in 3065 (16.8%) visits, and 292 (12.5%) patients had neutropenia, in 622 (3.4%) visits. After multivariable analyses, lymphopenia was associated with overall disease activity, ESR, serology, prednisolone, AZA, MTX, tacrolimus, CYC and rituximab use. MTX and ciclosporin were negatively associated with neutropenia. Lupus low disease activity state was negatively associated with both lymphopenia and neutropenia. Conclusion. Both lymphopenia and neutropenia were common in SLE patients but were differentially associated with disease and treatment variables. Lymphopenia and neutropenia should be considered independently in studies in SLE.
| Item Type: | Article |
|---|---|
| Funders: | AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EMD Serono, GlaxoSmithKline |
| Uncontrolled Keywords: | Leucopenia;Lymphopenian;Eutropenia;SLE disease activity;LLDAS;Medications |
| Subjects: | R Medicine R Medicine > RL Dermatology |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 26 Oct 2022 03:54 |
| Last Modified: | 26 Oct 2022 03:54 |
| URI: | http://eprints.um.edu.my/id/eprint/35374 |
Actions (login required)
 |
View Item |
